Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling 2,050,094 shares, a drop of 15.3% from the January 29th total of 2,419,408 shares. Currently, 5.5% of the shares of the company are short sold. Based on an average daily volume of 329,823 shares, the short-interest ratio is presently 6.2 days. Based on an average daily volume of 329,823 shares, the short-interest ratio is presently 6.2 days. Currently, 5.5% of the shares of the company are short sold.

Werewolf Therapeutics Trading Up 1.4%

HOWL opened at $0.62 on Friday. The company has a market cap of $30.16 million, a P/E ratio of -0.38 and a beta of 0.78. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. The company’s 50 day moving average is $0.64 and its 200-day moving average is $1.09. Werewolf Therapeutics has a 1-year low of $0.53 and a 1-year high of $2.38.

Analysts Set New Price Targets

Several equities analysts have weighed in on HOWL shares. Wedbush cut Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. Bank of America reduced their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. HC Wainwright decreased their target price on shares of Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, December 19th. Zacks Research downgraded shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $3.75.

Insider Transactions at Werewolf Therapeutics

In other news, Director Luke Evnin sold 58,980 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $0.57, for a total transaction of $33,618.60. Following the transaction, the director directly owned 2,309,869 shares of the company’s stock, valued at approximately $1,316,625.33. This trade represents a 2.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders sold 891,850 shares of company stock valued at $635,050. Insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Y Intercept Hong Kong Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter worth about $92,000. Bank of America Corp DE grew its holdings in shares of Werewolf Therapeutics by 1.2% during the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock valued at $429,000 after buying an additional 221,766 shares during the period. Jane Street Group LLC acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $409,000. Finally, Citadel Advisors LLC bought a new position in Werewolf Therapeutics in the 3rd quarter valued at approximately $304,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.